The question of a link between insulin-like growth factor physiology and neoplasia

Growth Hormone and IGF Research

Volumn 10, Issue SUPPL. B, 2000, Pages

  Pollak, M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer biology; Cancer risk; Epidemiology; Growth hormone; Insulin like growth factor I

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN C;

CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; GENE EXPRESSION; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033897155     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(00)80005-2     Document Type: Review

References (40)

1. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
2. Plasma insulin-like growth factor-(IGF-I) concentrations in human breast cancer
3. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
4. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
5. Insulin-like growth factor I and prostate cancer risk: A population-based, case-control study
6. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast
7. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
8. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3
9. Nutritional regulation of the insulin-like growth factors
10. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53 deficient mice
11. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor I and insulin-like growth factor-binding protein 3 concentrations in healthy adults
12. Growth hormone as a risk for premature mortality in healthy subjects: Data from the Paris prospective study
13. Cell proliferation in carcinogenesis
14. Normal growth and development in the absence of hepatic insulin-like growth factor I
15. Growth hormone treatment induces mammary gland hyperplasia in aging primates
16. Insulin-like growth factors and prostate cancer
17. Gene expression profiles in normal and cancer cells
18. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-b1 on programmed cell death through a p53- and IGF-independent mechanism
19. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer
20. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
21. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen
22. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
23. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins
24. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5
25. Castration-induced apoptosis of androgen-dependent Shinogi carcinoma is associated with increased expression of genes encoding IGF-binding proteins
26. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins
27. 3 and its analog EB1089
28. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor binding protein 5 accumulation
29. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
30. Controlling IGF-receptor function: A possible strategy for tumor therapy
31. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation
32. Mechanism of antineoplastic action of somatostatin analogues
33. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(α)anthracene-induced rat mammary carcinomas
34. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast cancer
35. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
36. Circulating IGF-I: A new perspective for a new century
37. The endocrinology of aging
38. Premature mortality due to cardiovascular diseases in hypopituitarism